Abstract
Multi-arm constructs were synthesized and used in three different contexts, all involving pathogenic bacteria. Glycodendrimers containing either the GM1os ligand or its greatly simplified relative galactose, were found to be very strong cholera toxin inhibitors, especially at higher valencies. Related glycodendrimers containing the galabiose epitope were strong inhibitors of the adhesion of the bacterial pathogen Streptococcus suis. Finally, a synthetic vaccine against Bordetella pertussis was prepared by conjugating three different relevant peptidic epitopes to a single scaffold.
Anti-Infective Agents in Medicinal Chemistry
Title: Multivalent Presentation Strategies in Novel Inhibitors of Bacterial (Toxin) Adhesion and Synthetic Vaccines
Volume: 7 Issue: 3
Author(s): Roland J. Pieters and Rob M.J. Liskamp
Affiliation:
Abstract: Multi-arm constructs were synthesized and used in three different contexts, all involving pathogenic bacteria. Glycodendrimers containing either the GM1os ligand or its greatly simplified relative galactose, were found to be very strong cholera toxin inhibitors, especially at higher valencies. Related glycodendrimers containing the galabiose epitope were strong inhibitors of the adhesion of the bacterial pathogen Streptococcus suis. Finally, a synthetic vaccine against Bordetella pertussis was prepared by conjugating three different relevant peptidic epitopes to a single scaffold.
Export Options
About this article
Cite this article as:
Pieters J. Roland and Liskamp M.J. Rob, Multivalent Presentation Strategies in Novel Inhibitors of Bacterial (Toxin) Adhesion and Synthetic Vaccines, Anti-Infective Agents in Medicinal Chemistry 2008; 7 (3) . https://dx.doi.org/10.2174/187152108784911269
DOI https://dx.doi.org/10.2174/187152108784911269 |
Print ISSN 1871-5214 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6018 |
Related Articles
-
Advances in Neuroimaging for HIV-1 Associated Neurological Dysfunction: Clues to the Diagnosis, Pathogenesis and Therapeutic Monitoring
Current HIV Research Migraine Attack Treatment : A Tailor-made Suit, Not One Size Fits All
Recent Patents on CNS Drug Discovery (Discontinued) Serum Tryptophan, Tryptophan Catabolites and Brain-derived Neurotrophic Factor in Subgroups of Youngsters with Autism Spectrum Disorders
CNS & Neurological Disorders - Drug Targets Interleukin-18, From Neuroinflammation to Alzheimers Disease
Current Pharmaceutical Design Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Immune Restoration Disease: A Consequence of Dysregulated Immune Responses After HAART
Current HIV Research Drug Development Against Sleeping Sickness: Old Wine in New Bottles?
Current Medicinal Chemistry Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Atranorin – An Interesting Lichen Secondary Metabolite
Mini-Reviews in Medicinal Chemistry Identification of Antibacterial Molecule(s) from Animals Living in Polluted Environments
Current Pharmaceutical Biotechnology Biologically Active Antimicrobial Compounds from Marine Microorganisms (2005-2019)
Current Pharmaceutical Biotechnology Liposomes as Potential Carrier System for Targeted Delivery of Polyene Antibiotics
Recent Patents on Inflammation & Allergy Drug Discovery subject Index To Volume 2
Current Medicinal Chemistry - Central Nervous System Agents The Influence of Traumatic Lumbar Puncture (TLP) on Outcome of Pediatric Patients
Current Pediatric Reviews Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Infectious Disorders - Drug Targets Recombinant Secretory Immunoglobulin A in Passive Immunotherapy: Linking Immunology and Biotechnology
Current Pharmaceutical Biotechnology Ligand-modified Biopolymeric Nanoparticles as Efficient Tools for Targeted Cancer Therapy
Current Pharmaceutical Design Therapeutic Targets for the Prevention of Type 1 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders